European Organization for Research and Treatment of Cancer

By V. Preedy, R. Watson. 2010

1,242 citations recorded by the source corpus.

View Paper: https://www.semanticscholar.org/paper/ad86dee1e31bf96b05f0f1a00de20ad90ea0489d

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Reproductive Medicine

Citations in the corpus

Aspergillus fumigatus and Aspergillosis in 2019 (2019, methodology): “This test is the most extensively used in clinics, has been validated in clinical studies, and has been endorsed in microbiological criteria for diagnosis of IA in all published guidelines (25, 93, 94).”
Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium (2019, methodology): “As before, a host factor has been defined as a characteristic of individuals clearly predisposed to, and not simply at risk of, an IFD [1].”
Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials. (2009, neutral): “Hewlett et al,13 1995 S8125 1982-1986 28 (16-49) 32 (13-39)b 111 (83-142) No No NR NR”
Autophagy-Dependent Anticancer Immune Responses Induced by Chemotherapeutic Agents in Mice (2011, background): “Similarly, clinical studies indicate that severe lymphopenia negatively affects the chemotherapeutic response of solid cancers (3), and immune defects are negative predictors of the response to chemotherapy with anthracyclines or oxaliplatin (2, 4, 5).”
Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines. (2011, background): “respectively, has been reported in retroperitoneal lymph nodes versus 29% and 33% at extranodal sites [77,78].”
PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. (2009, background): “Treatment was continued until progressive disease (PD) or toxicity occurred, according to the standard criteria (17).”
Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy. (2008, methodology): “compared with radiotherapy used in the definitive setting.(5,6) The question is”